The Globe and Mail reports in its Tuesday, Nov. 7, edition that CIBC Capital Market analyst Kevin Chiang has elevated his recommendation for Andlauer Healthcare Group to "outperformer" from "neutral." The Globe's David Leeder writes in the Eye On Equities column that Mr. Chiang continues to target the shares at $47.50. Analysts on average target the shares at $49.92. Mr. Chiang says the "visibility on post-pandemic earnings" has improved. Mr. Chiang says in a note: "We now see the company trading at trough multiples on trough earnings. We continue to have a favourable long-term outlook for the company as it benefits from a less cyclical organic growth model plus M&A optionality." The Globe reported on Nov. 11, 2022, March 7, 2023, and Aug. 4, 2023, that RBC Capital analyst Walter Spracklin had reiterated his "sector perform" call for Andlauer when it could be had for $50.45, $47.25 and $41.07. The Globe reported on May 9, 2023, that Scotia Capital analyst Konark Gupta had reaffirmed his "sector perform" recommendation for Andlauer Healthcare. The shares could then be had for $47.45.